Rofecoxib /ˌrɒfᵻˈkɒksɪb/ is a nonsteroidal anti-inflammatory drug (NSAID) that
has now been withdrawn over safety concerns. It was marketed by Merck ...
Rofecoxib (Vioxx) was withdrawn from the U.S. market in 2004. Rofecoxib is in a
class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Rofecoxib ...
Get information on the arthritis drug rofecoxib (Vioxx) removed from the US
market by the manufacturer.
Sep 30, 2004 ... Merck & Co., Inc., has announced a voluntary withdrawal of rofecoxib (Vioxx)
from the U.S. and worldwide market due to safety concerns of an ...
Original Article from The New England Journal of Medicine — Cardiovascular
Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention ...
Oct 26, 2004 ... Merck & Co. announced Sept. 30 a voluntary worldwide withdrawal of rofecoxib (
Vioxx) after a study showed patients taking the drug on a ...
Rofecoxib is a nonsteroidal anti-inflammatory drug that was used in the treatment
of osteoarthritis, acute pain conditions, and dysmenorrhoea. Formerly ...
Jun 13, 2005 ... Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic
compounds containing a 1,2-diphenylethylene moiety.
Oct 7, 2004 ... Then came the prospective APPROVe Study and MERCK removed rofecoxib
from the market. In sharp opposite to the results of Solomon et al.
Overview. Name: Rofecoxib Synonyms: Vioxx™ Therapy Type: Small Molecule (
timeline) Target Type: Inflammation (timeline) Condition(s): Alzheimer's Disease